ERBB2 and urinary bladder carcinoma: Trastuzumab does not cross the blood–brain barrier [17], suggesting that targeting Her2/neu positive systemic disease may alter the natural history of bladder carcinoma metastasis predisposing to the onset and progression of central nervous system (CNS) disease.